Targeting of activated T-cells with natural cytotoxic antibodies via an IL2-hapten conjugate prolongs graft survival.
Lussow
A R
AR
SangStat Medical Corporation, Menlo Park, California 94025, USA.
Fanget
L
L
Gao
L
L
Buelow
R
R
Pouletty
P
P
D000818:Animals; D015478:Antigens, Heterophile / Q000276:immunology*; D002240:Carbohydrate Sequence; D003602:Cytotoxicity, Immunologic; D004187:Disaccharides / Q000276:immunology*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D006241:Haptens; D016027:Heart Transplantation / Q000276:immunology*; D007165:Immunosuppression Therapy; D007376:Interleukin-2 / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D013601:T-Lymphocytes / Q000276:immunology*; D014183:Transplantation, Heterologous / Q000276:immunology*; D014184:Transplantation, Homologous / Q000276:immunology
D015478:Antigens, Heterophile; D004187:Disaccharides; D006241:Haptens; D007376:Interleukin-2; C055075:galactosyl-(1-3)galactose